- Get link
- X
- Other Apps
The purpose of this article is to provide an expert, stepwise playbook to improve solubility and rescue stalled dissolutions in laboratories and manufacturing settings.
1. Diagnose the Root Cause Before Changing Anything
Confirm identity, purity, and solid form by FTIR, DSC, and PXRD when available.
Check for polymorph changes, hydrates, or caking that reduce wettability.
Measure pH, temperature, and ionic strength of the medium at the point of failure.
Verify mixing energy, vortex depth, and actual shear at the solid–liquid interface.
Quantify residual air in filters or lines that can trap hydrophobic powders.
2. Choose the Right Solvent Using Cohesive Energy Arguments
Match solute and solvent polarity using Hildebrand or Hansen parameters where possible.
| Approach | What to Check | Practical Tip |
|---|---|---|
| Hildebrand (δ) | |δsolute − δsolvent| small. | Screen water, ethanol, isopropanol, acetone, acetonitrile, ethyl acetate, DMSO. |
| Hansen (δD, δP, δH) | Distance in Hansen space. | Blend two solvents to move toward the solute point. |
| Dielectric constant | Ionic solutes prefer higher ε. | Add water or formamides to increase polarity if compatible. |
Caution: Never exceed flash point or closed-cup limits during heated screens.
3. Use pH to Leverage Ionization for Weak Acids and Bases
Adjust pH to favor the ionized form and increase apparent solubility.
# Henderson–Hasselbalch quick checks # Weak acid: S = S0 * (1 + 10^(pH - pKa)) # Weak base: S = S0 * (1 + 10^(pKa - pH)) # Example: For a weak acid with S0=0.1 mg/mL, pKa=4.5, target S=10 mg/mL. # Needed ratio = S/S0 = 100 => 1 + 10^(pH - 4.5) = 100 => pH ≈ 6.5. Use Good’s buffers or pharmacopeial media to maintain pH under load.
Caution: Keep the final pH within product or method specifications and assess stability of the ionized form.
4. Salt Formation and Counterion Selection
Convert weak acids to sodium, potassium, or tromethamine salts to improve aqueous solubility.
Convert weak bases to hydrochloride, mesylate, or acetate salts when appropriate.
Screen counterions for hygroscopicity, crystallinity, and downstream compatibility.
5. Co-Solvent and Solvent-Blend Strategies
Add a miscible organic co-solvent to disrupt solvent structure and lower activity coefficients.
| Co-solvent | Typical Range | Notes |
|---|---|---|
| Ethanol or isopropanol | 5–40% v/v. | Food and pharma friendly, watch precipitation when diluted. |
| Acetonitrile | 5–60% v/v. | Strong polarity shift, volatile, toxicological limits apply. |
| DMSO or DMF | 1–20% v/v. | Powerful but carryover and toxicity concerns. |
| PEG 400 or propylene glycol | 10–80% v/v. | Enhances solubility and viscosity, slows diffusion. |
6. Surfactants and Wetting Agents
Use nonionic surfactants like polysorbate 20 or poloxamers to lower interfacial tension.
For hydrophobic APIs add 0.05–1% w/v surfactant and confirm CMC is exceeded.
Apply short ultrasonication bursts to break surface rafts and improve wetting.
Caution: Surfactants can interfere with assays and light scattering measurements.
7. Complexation and Inclusion Hosts
Employ cyclodextrins to encapsulate hydrophobic moieties and raise apparent solubility.
Screen α, β, and γ derivatives including HP-β-CD for solubility and taste masking in drug products.
8. Particle Engineering to Increase Surface Area
Reduce particle size by jet milling or wet media milling to increase dissolution rate.
Create amorphous solid dispersions or co-amorphous systems to raise apparent solubility.
Use spray drying or hot-melt extrusion to load drug into hydrophilic carriers.
9. Temperature, Mixing, and Degassing Controls
Increase temperature within specification to accelerate dissolution kinetics.
Use overhead stirring with a pitched-blade impeller for viscous or high-solids slurries.
Deaerate media to prevent bubble adhesion on hydrophobic surfaces.
10. Ionic Strength and Cosalt Effects
For ionic solutes adjust ionic strength to reduce activity coefficients where beneficial.
Avoid salting-out for nonpolar solutes by limiting strong electrolytes.
11. Antisolvent and pH-Shift Crystallization Control
If precipitation occurs on dilution, redesign the process to avoid crossing the binodal.
Use pH-shift loading into a high-solubility zone, then neutralize under controlled mixing if crystallization is intended.
12. Solid Form and Polymorph Management
Screen for metastable forms with higher solubility but confirm physical stability.
Use seed control and temperature ramps to avoid conversion to low-solubility forms.
13. Filtration and Sample Prep for Analytical Methods
Prewet hydrophobic filters with a small volume of solvent to prevent analyte adsorption.
Use low-binding PVDF or PTFE when working with nonpolar solutes.
Back-flush syringes before injection when microbubbles persist.
14. Decision Tree for Rapid Troubleshooting
| Observation | Likely Cause | High-Leverage Fix |
|---|---|---|
| Powder floats and clumps. | Poor wettability and trapped air. | Add 0.1% surfactant, pre-wet with a small volume of water-miscible solvent, sonicate 30 seconds. |
| Clear at high organic, precipitates on dilution. | Supersaturation collapse. | Introduce buffer capacity, add cyclodextrin, or maintain organic fraction during addition. |
| Slow but monotonic rise in concentration. | Surface area limited. | Mill finer, increase agitation, and raise temperature within specification. |
| No improvement with pH change. | Nonionizable solute. | Switch to co-solvent blend, surfactant, or inclusion complex. |
| Large batch variability. | Polymorph or hydrate shifts. | Control water activity and seed a single form. |
15. Validation and Stability After You Succeed
Map solubility versus pH, temperature, and solvent fraction to define a safe operating window.
Run accelerated and real-time stability to detect back-crystallization or chemical degradation.
Document cleaning validation for sticky high-solubility formulations.
Worked Examples
# Example 1. Raise solubility of a weak base (pKa 7.8) to 20 mg/mL. # Given S0=0.05 mg/mL at pH 7.0. # S/S0 = 400 => 1 + 10^(pKa - pH) = 400. # 10^(7.8 - pH) = 399 => 7.8 - pH = log10(399) ≈ 2.60 => pH ≈ 5.2. # Use acetate buffer pH 5.2, confirm chemical stability at this pH.
Example 2. Hydrophobic neutral compound fails to wet.
Action set: 0.5% poloxamer, 20% ethanol co-solvent, 40°C bath, overhead stirrer at 400 rpm.
Result: Complete dissolution in 12 minutes without foam formation.
Template SOP Snippet
1. Verify identity and solid form via DSC and PXRD references if available. 2. Measure pH and temperature of the medium. Record to one decimal place. 3. If ionizable, adjust pH toward ionized state using validated buffer. 4. Add surfactant to 0.2% w/v if wetting failure is observed. 5. Increase temperature by 5–10°C within specification. Maintain constant agitation. 6. If still failing, add 10–30% v/v co-solvent in 5% increments with mixing. 7. Confirm clarity by 0.45 μm filtration. Inspect for Tyndall effect. 8. Record final composition, pH, temperature, and dissolution time.FAQ
How do I prevent precipitation after dilution?
Match the diluent composition to keep the system above the solubility curve, add buffer capacity, or include cyclodextrin or a low-level surfactant to maintain supersaturation long enough for testing.
When should I choose salt formation over co-solvents?
Choose salt formation for ionizable APIs intended for aqueous systems or oral dosing. Use co-solvents for rapid screening, for neutrals, or when regulatory limits permit the chosen solvent fraction.
Can I combine particle size reduction with surfactants?
Yes. Milled particles benefit from surfactants that prevent agglomeration and keep the increased surface area accessible to the medium.
What if pH that gives high solubility causes instability?
Use minimal pH shift combined with a co-solvent, complexation, or a salt that is stable at a milder pH. Verify with accelerated stability and assay for degradation products.